https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-august-10-2026/ 2026-08-11T20:38:03Z Pharminent en Rare Disease & Gene Therapy Digest • August 10, 2026 2026-08-11T20:37:59Z Blog https://pharminent.com/trump-executive-order-strips-seven-vaccines-from-childhood-immunization-recommendations/ 2026-08-11T20:17:11Z Pharminent en Trump Executive Order Strips Seven Vaccines From Childhood Immunization Recommendations 2026-08-11T20:04:51Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-11-2026/ 2026-08-11T19:23:36Z Pharminent en Strategic News Watch • August 11, 2026 2026-08-11T19:23:32Z Blog https://pharminent.com/chasing-dupixent-a-biotech-aims-to-make-better-antibody-drugs-for-eczema/ 2026-08-11T19:25:15Z Pharminent en Chasing Dupixent, a biotech aims to make better antibody drugs for eczema 2026-08-11T13:40:00Z Blog https://pharminent.com/bms-banks-on-texas-for-2-3bn-multi-modal-manufacturing-facility/ 2026-08-11T19:26:07Z Pharminent en BMS banks on Texas for $2.3bn multi-modal manufacturing facility 2026-08-11T10:25:55Z Blog https://pharminent.com/jazz-pharmaceuticals-to-acquire-actio-biosciences-for-820m-upfront/ 2026-08-11T19:29:46Z Pharminent en Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront 2026-08-11T09:31:06Z Blog https://pharminent.com/jazz-pharmaceuticals-acquires-actio-biosciences-for-820m-upfront/ 2026-08-10T19:51:47Z Pharminent en Jazz Pharmaceuticals Acquires Actio Biosciences for $820M Upfront 2026-08-10T19:51:44Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-august-7-2026/ 2026-08-10T16:18:56Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • August 7, 2026 2026-08-10T16:18:53Z Blog https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-august-7-2026/ 2026-08-10T16:16:03Z Pharminent en GLP-1 Competitive Market Digest • Weekly • August 7, 2026 2026-08-10T16:16:01Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-august-7-2026/ 2026-08-10T16:11:09Z Pharminent en Oncology Intelligence Digest • August 7, 2026 2026-08-10T16:11:06Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-10-2026/ 2026-08-10T16:02:18Z Pharminent en Strategic News Watch • August 10, 2026 2026-08-10T16:02:17Z Blog https://pharminent.com/biomarin-axes-asset-from-270m-inozyme-takeover-ending-run-in-rare-metabolic-indication/ 2026-08-11T19:27:16Z Pharminent en BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication 2026-08-10T11:20:01Z Blog